HBK Sorce Advisory’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $647K | Sell |
4,005
-12
| -0.3% | -$2.26K | 0.01% | 342 |
|
|
2026
Q1 | $735K | Buy |
+4,017
| New | +$775K | 0.01% | 300 |
|
|
2025
Q4 | – | Sell |
-3,893
| Closed | -$660K | – | 632 |
|
|
2025
Q3 | $660K | Sell |
3,893
-9
| -0.2% | -$1.36K | 0.02% | 299 |
|
|
2025
Q2 | $545K | Buy |
3,902
+46
| +1% | +$6.45K | 0.01% | 324 |
|
|
2025
Q1 | $567K | Buy |
3,856
+12
| +0.3% | +$1.74K | 0.02% | 312 |
|
|
2024
Q4 | $504K | Sell |
3,844
-219
| -5% | -$30.7K | 0.02% | 335 |
|
|
2024
Q3 | $633K | Sell |
4,063
-351
| -8% | -$56.7K | 0.02% | 289 |
|
|
2024
Q2 | $688K | Buy |
4,414
+165
| +4% | +$24.8K | 0.02% | 270 |
|
|
2024
Q1 | $576K | Buy |
4,249
+98
| +2% | +$13K | 0.02% | 309 |
|
|
2023
Q4 | $559K | Sell |
4,151
-43
| -1% | -$5.59K | 0.02% | 295 |
|
|
2023
Q3 | $568K | Buy |
4,194
+24
| +0.6% | +$3.28K | 0.03% | 286 |
|
|
2023
Q2 | $597K | Sell |
4,170
-86
| -2% | -$12.7K | 0.03% | 291 |
|
|
2023
Q1 | $591K | Sell |
4,256
-4,687
| -52% | -$631K | 0.03% | 294 |
|
|
2022
Q4 | $1.21M | Buy |
8,943
+2,282
| +34% | +$286K | 0.03% | 254 |
|
|
2022
Q3 | $672K | Buy |
6,661
+985
| +17% | +$125K | 0.05% | 210 |
|
|
2022
Q2 | $750K | Sell |
5,676
-1,534
| -21% | -$201K | 0.06% | 190 |
|
|
2022
Q1 | $957K | Sell |
7,210
-1,985
| -22% | -$238K | 0.05% | 204 |
|
|
2021
Q4 | $1.07M | Buy |
9,195
+171
| +2% | +$20.1K | 0.05% | 205 |
|
|
2021
Q3 | $1.08M | Buy |
9,024
+1,076
| +14% | +$125K | 0.06% | 196 |
|
|
2021
Q2 | $952K | Buy |
7,948
+1,426
| +22% | +$156K | 0.05% | 205 |
|
|
2021
Q1 | $649K | Sell |
6,522
-733
| -10% | -$73.7K | 0.04% | 250 |
|
|
2020
Q4 | $725K | Sell |
7,255
-1,274
| -15% | -$135K | 0.04% | 224 |
|
|
2020
Q3 | $935K | Sell |
8,529
-1,397
| -14% | -$155K | 0.07% | 181 |
|
|
2020
Q2 | $1.05M | Buy |
9,926
+6,692
| +207% | +$691K | 0.08% | 165 |
|
|
2020
Q1 | $289K | Buy |
3,234
+761
| +31% | +$71.6K | 0.03% | 298 |
|
|
2019
Q4 | $247K | Buy |
+2,473
| New | +$233K | 0.02% | 372 |
|
|
2018
Q2 | – | Sell |
-3,033
| Closed | -$212K | – | 390 |
|
|
2018
Q1 | $212K | Sell |
3,033
-120
| -4% | -$8.31K | 0.03% | 343 |
|
|
2017
Q4 | $219K | Buy |
+3,153
| New | +$213K | 0.03% | 352 |
|
Other funds holding AZN
EP
IA
HBK Sorce Advisory's AZN Position: Q2 2026 in Review
HBK Sorce Advisory reduced its AstraZeneca (AZN) stake by 0.3% in Q2 2026, selling an estimated $2.26K and leaving 4,005 shares worth $647K. The position accounts for 0.01% of the portfolio, ranked #342.
HBK Sorce Advisory first reported a position in AZN in Q4 2017 and has held it in 28 quarters since. The position peaked at $1.21M in Q4 2022. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- HBK Sorce Advisory held 4,005 shares of AstraZeneca worth $647K as of Q2 2026.
- HBK Sorce Advisory sold 12 AstraZeneca shares in Q2 2026, an estimated $2.26K.
- AstraZeneca made up 0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #342 holding.
- HBK Sorce Advisory first reported a position in AstraZeneca in Q4 2017 and has held it in 28 quarters since.
- HBK Sorce Advisory's AstraZeneca position peaked at $1.21M in Q4 2022.
- 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.